IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
Fundz sees it the moment IceCure Medical raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CaesareaManufacturingBiotechnologyHealth CareMedicalMedical Devicemedical devices